skip to main content columnskip to left navigationskip to horizontal navigation

Bill Gatton College of Pharmacy

East Tennessee State University

Profile Image

Sam  Harirforoosh 

PharmD, PhD
423-439-2074 /
Building 7, Room 320



Google Scholar Citations

Publons Peer Review Profile

Education, Degree, & Post Graduate Training:

  • PharmD, Tehran University of Medical Sciences, 1991
  • PhD, Pharmaceutical Sciences (Pharmacokinetics), University of Alberta, 2005
  • Research Assistant/Post-doctoral Fellow, Pulmonary Research Group, Dept. of Medicine, Univ. of Alberta, June 2005-May 2006

Editorial Board Memberships:

  • Clinical Pharmacokinetics
  • European Journal of Drug Metabolism and Pharmacokinetics

Classes Taught:

Pharmacokinetics & Pharmacogenomics, Course coordinator and lecturer
Pharmaceutics & Biopharmaceutics, Lecturer
Advanced Pharmacokinetics (Graduate course), Course coordinator and lecturer
Advanced Drug Metabolism (Graduate course), Course coordinator and lecturer
General Principles of Pharmacology (Graduate course), Lecturer
Non-Medicinal Drug Use (Elective course), Lecturer
Compounding and Dispensing Lab, Instructor
Integrated Series IV - Renal, Lecturer
Pharmaceutical Sciences Research I, II, III and IV (Elective courses)

Research Interests:

Cardiovascular and Renal Adverse Effects of Drugs
Pharmacokinetic/Pharmacodynamic Modeling
Nanoparticle Formulation of Drugs

Selected Publications: 

Jim Thigpen, Brian Odle, and Sam Harirforoosh. 2019. Opioids: A review of pharmacokinetics and pharmacodynamics in neonates, infants, and children. European Journal of Drug Metabolism and Pharmacokinetics. 44: 591-609 

Brooks B. Pond, Stacy D. Brown, David W. Stewart, David S. Roane, and Sam Harirforoosh. 2019. Faculty Applicants Attempt to Inflate CVs Using Predatory Journals. American Journal of Pharmaceutical Education. 83: 12-14 

Derek E. Murrell, David B. Cluck, Jonathan P. Moorman, Stacy D. Brown, Ke-Sheng Wang, Michelle M. Duffourc, and Sam Harirforoosh. 2019. HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study. Clinical Drug Investigation. 39: 285-299

Aaron J. Salwan, Nicholas E. Hagemeier, and Sam Harirforoosh. 2018. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters? Clinical Drug Investigation. 38:573–577 

Bryan R. Gunter, Kristen A. Butler, Richard L. Wallace, Steven M. Smith, and Sam Harirforoosh. 2017. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis. Journal of Clinical Pharmacy and Therapeutics. 42: 27-38

Crystal L. Whitted, Victoria E. Palau, Ruben D. Torrenegra, Oscar E. Rodriguez, and Sam Harirforoosh. 2017. Quantification of two isomeric flavones in rat colon tissue using reverse phase high performance liquid chromatography. BMC Research Notes. 10:29

Daniel Owusu, Yue Pan, Changchun Xie, Sam Harirforoosh, and Ke-Sheng Wang. 2017. Polymorphisms in PDLIM5 gene are associated with alcohol dependence, type 2 diabetes, and hypertension. Journal of Psychiatric Research. 87: 27-34

Derek E. Murrell, Ronald L. Carico, John B. Bossaer, Sam Harirforoosh, and David B. Cluck. 2017. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections. International Journal of Pharmacy Practice. 25: 18-30

Sam Harirforoosh and David W. Stewart. 2016. A descriptive investigation of the impact of student research projects arising from elective research courses. BMC Research Notes. 9:48

Derek E. Murrell and Sam Harirforoosh. 2016. Improving the renal profile of a HIV drug combination through prodrug alteration. Journal of Integrative Nephrology and Andrology. 3:1-2

Crystal Whitted, Victoria Palau, Ruben Torrenegra, and Sam Harirforoosh. 2015. Development of reversed-phase high performance liquid chromatography methods for quantification of two isomeric flavones and the application of the methods to pharmacokinetic studies in rats. Journal of Chromatography B. 1001:150-155 

Derek E. Murrell, Jonathan P. Moorman, and Sam Harirforoosh. 2015. Stribild: a review of component characteristics and combination drug efficacy. European Review for Medical and Pharmacological Sciences. 19: 904-914 

Dustin L. Cooper and Sam Harirforoosh. 2014. Effect of formulation variables on preparation of celecoxib loaded polylactide-co-glycolide nanoparticles. PLoS ONE. 9(12): e113558 

Sam Harirforoosh, Waheed Asghar, and Fakhreddin Jamali. 2013. Adverse Effects of Nonsteroidal Anti-inflammatory Drugs: An update of Gastrointestinal, Cardiovascular, and Renal Complications. Journal of Pharmacy & Pharmaceutical Sciences. 16 (5): 821-847

Robert C. Wood III, Jarrett E. Wyatt, Kenny W. Bullins, Angela V. Hanley, Gregory. A. Hanley, James W. Denham, Peter C. Panus, and Sam Harirforoosh. 2013. Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats. European Journal of Pharmacology. 720: 138-146

Jarrett E. Wyatt, Wesley L. Pettit, and Sam Harirforoosh. 2012. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. The Pharmacogenomics Journal. 12: 462-467

Organizational Involvement/Membership: 

American College of Clinical Pharmacology
American Association of College of Pharmacy
Alberta College of Pharmacists

icon for left menu icon for right menu